Display Settings:

Format

Send to:

Choose Destination

    Ann Intern Med. 1975 Apr;82(4):499-505.

    Meningeal mycosis fungoides: clinical and cellular characteristics.

    Hauch TW, Shelbourne JD, Cohen HJ, Mason D, Kremer WB.

    A patient with mycosis fungoides developed meningeal disease while his skin disease was in remission with systemic chemotherapy. His central nervous system involvement with mycosis fungoides was controlled with intrathecal methotrexate for 7 months. The proliferating cells recovered from the spinal fluid showed similarities to the Sézary cell by light and electron microscopy. Surface receptor sutudies suggested that these cells were lymphoid cells of thymic derivation. Although mycosis fungoides has been shown to spread to the central nervous system in autopsied cases, reports of clinical neurologic disease are rare, and in only one earlier report have malignant cells have been found in the spinal fluid. Thus, as in other lymphoproliferative disorders, prompt consideration of meningeal involvement in a patient exhibiting neurologic symptoms while in peripheral remission may allow earlier treatment of this complication.

    PMID: 1168035 [PubMed - indexed for MEDLINE]

    Supplemental Content

    Patient drug information

    • Cyclophosphamide (Cytoxan®, Neosar®)

      Your doctor has ordered the drug cyclophosphamide to help treat your illness. The drug can be taken by mouth in tablet form or be given by injection into a vein.

    • Methotrexate (Rheumatrex®, Trexall®)

      Methotrexate is used to treat severe psoriasis (a skin disease in which red, scaly patches form on some areas of the body) that cannot be controlled by other treatments. Methotrexate is also used along with rest, physica...